Metabolic syndrome (Mets) is coming to the forefront globally and is widely believed to contribute to an increased risk of several cancers, such as urothelial carcinoma of the bladder (UCB) . Researchers conducted a study to assess the relationship between Mets and UCB. The investigators conducted a case-control study of 690 cancer patients and 665 non-cancer matched patients in Italy between 2003-2014. mets should fit at least 3 of the following: abdominal obesity, hypercholesterolemia, hypertension, and diabetes mellitus. Multifactorial logistic regression models were estimated correcting for potential confounders with ORs and 95% confidence intervals (CIs) between Mets and UCB’s. The study data showed a 2-fold increased risk of UCB in Mets compared to non-Mets patients (95% CI:1.38-3.19). The risk of bladder cancer in patients with diabetes OR=2.20 (95% CI:1.42-3.38), bladder cancer risk in patients with hypertension OR=0.88 (95% CI: 0.66-1.17), bladder cancer risk in patients with hypercholesterolemia OR=1.16 (95% CI: 0.80-1.67), and bladder cancer risk in patients with abdominal obesity OR=1.63 (95% CI:1.22-2.19). 2.19). There was no heterogeneity between the case and control groups in terms of gender, age, education, geographic area, and smoking habits. Overall 8.1% (95% CI: 3.9-12.4%) of UCB cases were attributed to Mets. The results of this study support previous studies that Mets increases bladder cancer risk.